COLORADO SPRINGS, Colo., July 8, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting applauds the legalization of medical marijuana usage in New York State opening the opportunity to help one of the largest US populations of patients with legal medical cannabis.
As Gov. Andrew Cuomo signed the Compassionate Care Act, one of the largest marketplaces for medical marijuana has opened up to companies focused on medical grade marijuana treatments. The legalization of medical marijuana has had "overwhelming support" in state polls, State Assembly Speaker Sheldon Silver has said in a statement. Cannabis Science has been actively involved in the procurement and initiation to place treatment and scientific research for the anticipated usage in New York State. With extremely high proliferation of usage numbers coming from Colorado, a state that has legalized both recreational and medical usage, Cannabis Science is extremely excited to see a population base of almost 20 million citizens be part of regulation reform. It is anticipated that these changes will also allow copious amounts of data to be gathered to provide evidence based therapy approach administered in a manner that protects public health and safety.
On the other side of the country after almost 2 years of anticipation, the first licenses for legal sale where issued yesterday and sales are intended to begin today in the state of Washington. Recreational dispensary candidates are currently applying and 20 of the 334 authorized permits have already been approved in the first wave of applications submitted to the state government.
These developments signify change in the lawmakers' attitudes and will continue driving changes in legalizing the use of medical marijuana worldwide. The Cannabis Science management board view these events as a progressive step to boost the cannabinoid science and the opportunity for the scientific innovations held by Cannabis Science to be developed in order to respond to the unmet medical needs in multiple markets.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
SOURCE Cannabis Science, Inc.